MDM2 and B-cell chronic lymphocytic leukemia: The ex-vivo drug response screen revealed that TP53-mutated CLL samples responded worse to chemotherapy and the MDM2 inhibitor nutlin 3a than TP53 wild-type samples (Fig. 2g), as expected32.